SynthesisFrontiers in pharmacology2026
Efficacy of combined sodium-glucose cotransporter 2 inhibitors and finerenone in chronic kidney disease: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sodium-glucose cotransporter two inhibitors (SGLT2is) and finerenone have demonstrated individual efficacy in reducing cardiorenal events among patients with diabetic chronic kidney disease (CKD). However, the additive benefits and safety profile of combining these agents remain unclear. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials and observational studies comparing finerenone plus SGLT2is Results: A total of eight studies (N = 1,580) were included. Compared with finerenone monotherapy, combination therapy significantly reduced all-cause mortality (OR 0.58; 95% CI: 0.36-0.93). Furthermore, combination therapy also reduced MACE risk (OR 0.70; 95% CI: 0.51-0.97) and major adverse kidney event (MAKE) risk (OR 0.63; 95% CI: 0.44-0.89) compared with finerenone monotherapy. Combination therapy significantly reduced urinary albumin-creatinine ratio (UACR) more than finerenone monotherapy, with a mean difference of 0.10 (equivalent to a 10% greater reduction; combination vs. finerenone, 95% CI: 0.00-0.19; Conclusion: Combining finerenone with SGLT2i may improve survival and reduced risks of MACEs and MAKEs compared with finerenone monotherapy in patients with diabetic CKD. These findings support careful consideration of dual therapy, especially in high-risk populations. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420251023918, identifier: CRD420251023918.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.